Printer Friendly

Sleep disturbances may precede PTSD.

BOSTON -- Sleep disturbances may be an important target for treating posttraumatic stress disorder, according to Dr. R. Bruce Lydiard of the Medical University of South Carolina in Charleston.

Persistent, severe posttraumatic nightmares, REM sleep fragmentation, insomnia, excessive nocturnal periodic limb movements, and sleep-disordered breathing are frequently experienced by individuals with PTSD, Dr. Lydiard said. Although these sleep problems are often viewed as secondary symptoms of PTSD, "the evidence suggests that after a traumatic event, sleep disruption appears before the onset of PTSD and may be a risk factor for it," he proposed.

Polysomnographic data from 21 individuals with traumatic injuries showed that the number of REM periods and the (shorter) duration of REM periods within 1 month after the traumatic event were predictive of PTSD symptom severity 6 weeks later (Am. J. Psychiatry 2002;159:1696-701).

Neurobiologically, the association makes sense, Dr. Lydiard said. "Sleep is regulated in part by brain areas in which PTSD-related changes occur," which suggests that the stress response in PTSD and sleep dysfunction may be biologically linked.

Imaging studies suggest that exposure to trauma-related stimuli leads to hyperactivation in the amygdala and decreased activation in the medial prefrontal cortex/anterior cingulate cortex and hippocampus, with the magnitude of the activation correlating with the clinical severity of PTSD symptoms.

Together with clinical reports, "these data provide the basis for REM sleep dysregulation as a core feature in PTSD," whereby increased activity in the amygdala and decreased inhibitory input from the medial prefrontal cortex lead to a persistently overactive noradrenergic system.

Investigators have hypothesized that targeting noradrenergic signaling during or near REM episodes may normalize REM sleep, which in turn might improve PTSD sleep disturbances and, potentially, other PTSD symptoms.

The alpha adrenergic antagonist prazosin has shown promise in multiple case and chart reviews, open-label trials, and placebo-controlled studies.

In one trial of 40 veterans with PTSD sleep disturbance, patients who were randomized to receive a nightly dose of prazosin--originally marketed as an antihypertensive agent--reported significant improvements in sleep quality and significant reductions in trauma nightmares, as well a better overall sense of well-being and improved daily functioning (Biol. Psychiatry 2007;61:928-34).

In another study, of 13 outpatients with chronic civilian trauma PTSD, frequent nightmares, and sleep disturbance, the prazosin group experienced significantly increased total sleep time as well as increased REM sleep time and mean REM period duration compared with a placebo group (Biol. Psychiatry 2008;63:629-32).

In the various studies, the therapeutic benefit of prazosin has been achieved within 1-2 weeks "with doses as low as 1 mg nightly," Dr. Lydiard said.

In addition to improving sleep measures, prazosin may be useful for other trauma-related symptoms. In a small study of PTSD subjects whose nightmares were well controlled with the drug, the addition of small daytime doses lessened patients' reactivity to trauma cues during the day, he said (Biol. Psychiatry 2006;59:577-81). This finding "adds to the growing body of evidence that targeting sleep in PTSD is clinically relevant."

Although some evidence exists to support the use of other antiadrenergic agents such as clonidine and guanfacine--as well as the anticonvulsant gabapentin--in PTSD, 'large, randomized controlled trials are needed to clarify the role" of all of these agents, Dr. Lydiard said.

Disclosures: Dr. Lydiard disclosed received honoraria from Reed Medical Education, the logistics collaborator for the Massachusetts General Hospital Psychiatry Academy.

COPYRIGHT 2010 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Mahoney, Diana
Publication:Internal Medicine News
Geographic Code:1USA
Date:Aug 1, 2010
Previous Article:H1N1 protection in seasonal flu vaccines for 2010-2011.
Next Article:Resiliency program channels returning vets' need for thrills.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters